News About: Pharm. Affairs
Price dualization for NIP cervical cancer vaccines
Cervical cancer vaccines for the National Immunization Program(NIP) which will be conducted from this June are expected to be decided at dualized prices.
According to the pharmaceutical industry, it was told the Kore...
Slowly changing metal illness treatments
Mental illness treatments introduced in Korea have experienced relatively minor changes compared to other diseases. It is also a problem for people to avoid getting treated as having prejudices and misunderstandings t...
Will ‘probiotics’ become hot in the market?
While a series of probiotics products have been launched in the pharmaceutical industry, the healthcare authorities started to prove their safety.
Recently, it was confirmed by a cover result that the Ministry of Foo...
Weigh-losing antidiabetic ‘Jardiance’ passed wall of the health insurance
A weight-losing antidiabetic ‘Jardiance’ will receive the health insurance benefits.
According to the industry concerned on the 18th, Boehringer Ingelheim and Lilly has recently made an agreement for the price of Jar...
Insurance benefit of Baraclude extended to children over 2A BMS Korea’s hepatitis B treatment, ‘Baraclude’ will be extended in the health insurance benefit to children over 2. Moreover, a Boehringer Ingelheim’s chronic obstructive pulm...
|
Pharmaceutical disputes focused on ‘composition/substance patents’
It has been a year since the enforcement of the Patent Linkage System(15 March 2015).
Although fierce conflicts were made among original companies owning patents and second movers during the period, ‘composition pate...
Will sales of ‘Enbrel’ increase by the launch of its biosimilar?
The launch of biosimilar ‘Brenzys’ decreased the health insurance benefit of ‘Enbrel’ by 30%, enlarging the price competition against Enbrel. Their prescriptions will be increased jointly through the effect of the lau...
Galderma’s gel-type facial flushing treatment about to be launched in Korea
A gel-type facial blushing treatment is expected to be commercialized in the domestic market.
According to the industry concerned on the 29th, Galderma has acquired domestic approval of ‘Mirvaso,’ a self-developed ge...
“Lenvima suggests a new option for radioiodine-refractory thyroid cancer”
A new treatment option was added in the radioiodine-refractory local recurrent or progressive differentiated thyroid cancer treatment.
Eisai Korea(CEO Hong-byung Goh) held a press conference to celebrate the launch ...
“Biosimilar prices should be accepted at 80% of the original prices”
A business conference for the biopharmaceutical drug pricing system opened. While relative issues were focused into 3 items, serious conversations were shared even on the first day, which means it was hard to find agr...
